Bidirectional cellular interactions between prostate cancer and prostate or bone stroma are needed for local tumor growth and distant metastasis. The genetics of cancer cells is affected by the host microenvironment and, reciprocally, permanent gene expression changes occur in the stroma surrounding epithelial cancer cells. The immune-mediated micromilieu also affects the progression of prostate cancer; the role of the immune system in controlling the growth of prostate cancer cells is complex, with immune escape mechanisms prevailing over effective antitumor response. Moreover, tumor stem cell models to explain the origin and progression of prostate cancer require appropriate environmental conditions. On the basis of a review of the literature, this article aims to outline the recent advances in the elucidation of the molecular mechanisms underlying the interactions between prostate cancer and its microenvironment.
BarretJ.M., MangoldK.A., JillingT., KaulK.L.Bidirectional interactions of prostate cancer cells and bone marrow endothelial cells in 3-D culture.The Prostate2005; 64: 75–82.
2.
ChambersA.F., GroomA.C., MacDonaldI.C.Dissemination and growth of cancer cells in metastatic sites.Nat Rev Cancer2002; 2: 563–70.
WangR., XuJ., JulietteL.Three-dimensional co-culture models to study prostate cancer growth, progression and metastasis to bone.Semin Cancer Biol2005; 15: 353–64.
13.
CukiermanE., PankovR., StevensD.R., YamadaK.M.Taking cell-matrix adhesions to the third dimension.Science2001; 294: 1661–3.
14.
SelliC., PapiniS., RoselliniA., De MatteisA., RevoltellaR.Three dimensional organ culture of human prostatic cancer and benign tissue.Eur Urol2005; 4(Suppl 3): P5–78, 22.
15.
BistolfiF.BCS: the bioconductive connectional system. In: BistolfiF.Biostructures and radiation: order disorder.Torino: Minerva Medica, 1991; 53–60.
16.
Del GiudiceE., FleischmannM., PreparataG., TalpoG.On the “unreasonable” effects of ELF magnetic fields upon a system of ions.Bioelectromagnetics2002; 23: 522–30.
17.
ScherenzelJ., SerranderL., BanfiB.Electron currents generated by the human phagocyte NADPH-oxidase.Nature1998; 392: 734–7.
18.
CavelierG.Theory of malignant cell transformation by superoxide fate coupled with cytoskeletal electron-transport and electron-transfer.Med Hypotheses2000; 54: 95–8.
19.
FuhK.C., MeneshianA., PatelC.B., TakiarV., BulkeyG.B.Signal transduction by ROS: alternative paradigms for signaling specificity.Surgery2002; 131: 601–12.
KimD.Y., YooT.G., ParkC.H., KimJ.W., YangE.K.Alterations in calcium-activated potassium channel expression in human prostate-cancer.Eur Urol2005; 4(Suppl): P42–721, 183.
22.
GeraldW.L.Genoma-wide gene expression analysis of prostate carcinoma.Semin Oncol2003; 30: 635–48.
23.
TrojanL., SteidlerA., HaakM.Identification of metastasis-associated genes in prostatic cancer by genetic profiling of human prostate cell lines.Eur Urol2005; 4(Suppl): P5–80, 22.
24.
ChungL.W.Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications.Cancer2003; 97: 772–8.
25.
PagetS.The distribution of secondary growths in cancer of the breast.Cancer1889; 1: 571–3.
26.
GleaveM., HsiehJ.T., GaoC.A., von EschenbachA.C., ChungL.W.Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.Cancer Res1991; 51: 3753–62.
27.
ChungL.W., BasemanA., AssikisV., ZhauH.E.Molecular insight into prostatic cancer progression: the missing link of tumor microenvironment.J Urol2005; 173: 10–20.
28.
KykerK.D., CulkinD.J., HurstR.E.A model for 3-D growth of bladder cancer to investigate cell-matrix interactions.Urol Oncol2003; 21: 255–61.
29.
HorinageM., OkitaH., NakashimaJ., KanaoK., SakamotoM., MuraiM.Clinical and pathologic significance of activation of STAT-3 in prostate cancer.Urology2005; 66: 671–5.
30.
ShariatS.F., Menessez-DiazA., KimI.Y., MuramotoM., WheelerT.M., SlawinK.M.Tissue expression of TGF-? and its receptors.Urology2004; 63: 1191–7.
31.
van der PoelH.G.Mammalian target of rapamycin and P13K pathway inhibition enhances growth inhibition of TGF-?1 in prostate cancer cells.J Urol2004; 172: 1333–7.
32.
WoodhouseE.C., ChuaquiR.F., LiottaL.A.General mechanism of metastasis.Cancer1997; 80(Suppl): 1529–31.
HillR., SongY., CardiffR.D., Dan DykeT.Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.Cell2005; 123: 1001–11.
35.
PathakS., NemethM.A., MultaniA.S., ThalmannG.N., von EschenbachA.C., ChungL.W.Can cancer cells transform normal host cells into malignant cells?Br J Cancer1997; 76: 1134–40.
36.
LiaoX., ThrasherJ.B., PellingJ., HolzbeierleinJ., SangQ.Z., LiB.Androgen stimulates MM2 expression in human prostate cancer.Endocrinology2003; 144: 1656–63.
Van der PoelH., BindelsE., WeijsL.Transforming growth factor-?1 and androgen signaling are mutually inhibitory in a prostate cancer cell line.Eur Urol2005; 4(Suppl): P5–84, 23.
FujiuchiY., NagakawaO., MurakamiK., FuseH., SaikiI.Effect of HGF on invasion of prostate cancer cell lines.Oncol Rep2003; 10: 1001–6.
41.
WrightM.E., TsaiM.J., AebersoldR.Androgen receptor represses neuroendocrine transdifferentiation process in prostate cancer cells.Molec Endocrinol2003; 17: 1726–37.
42.
HarrisA.L.Hypoxia, a key regulator factor in tumor growth.Nat Rev Cancer2002; 2: 38–47.
43.
ThieryJ.P.Epithelial-mesenchymal transition in tumor progression.Nat Rev Cancer2002; 2: 442–8.
44.
IngberD.E.Cancer as a disease of epithelial-mesencymal interactions and extracellular matrix interactions and extracellular matrix regulation.Differentiation2000; 70: 547–53.
45.
CooperC.R., ChayC.H., GendernalickJ.D.Stromal factors involved in prostate carcinoma metastasis to bone.Cancer2003; 97(Suppl 3): 739–47.
46.
TanakaM., KogawaZ., NishihoriY.Suppression of intracellular Cu-Zn SOD results in enhanced motility and metastasis in sarcoma cells.Int J Cancer1997; 73: 187–92.
47.
FarrahK., WernerE., TrembleP., SymonsM., WerbZ.Role of Rac1 and ROS in collagenase-1 expression induced by cell shape changes.Science1998; 280: 898–902.
48.
KoenemanK.S., YeungF., ChungL.W.Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.Prostate1999; 32: 246–61.
49.
ZhauH.E., LiC.L., ChungL.W.Establishment of human prostate carcinoma skeletal metastasis model.Cancer2000; 88(Suppl 12): 2995–3001.
50.
CherM.Mechanisms governing bone metastasis in prostate cancer.Curr Opin Urol2001; 11: 483–8.
51.
TaichmanR.S., CooperC., KellerE.T., PientaK.J., TaichmanN.S., McCarleyL.K.Use of stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.Cancer Res2002; 62: 1832–7.
52.
MasudaH., FukaboriY., NakanoK., TakezawaY., SuzukiT., YamanakaH.Increased expression of BMP-7 in bone metastatic prostate cancer.Prostate2003; 54: 268–74.
53.
JacobK., WebberM., BenayahuD., KleinmanA.K.Osteonectin promotes prostate cancer migration and invasion: a possible mechanism for metastasis to bone.Cancer Res1999; 59: 4453–7.
54.
HonnK.V., TangD.G.Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix.Cancer Metast Rev1992; 11: 353–75.
55.
KierszenbaumA.L., RivkinE., ChangP.L.Galactosyl receptor, a cell surface C-type lectin of normal and tumoral prostate epithelial cells with binding affinity to endothelial cells.Prostate2000; 43: 175–83.
56.
LehrJ.E., PientaK.T.Preferential adhesion of prostate cancer cells to human bone marrow endothelial cell line.J Natl Cancer Inst1998; 90: 118–23.
57.
De PalmaM., VenneriM.A., GalliR.Tie identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.Cancer Cell2005; 8: 211–26.
58.
BoguslawskiG., HaleL.V., YuX.P.Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways.J Biol Chem2000; 275: 999–1006.
59.
BrownJ.M., CoreyE., LeeZ.D.Osteoprotegerin and RANKL expression in prostate cancer.Urology2001; 57: 611–7.
60.
RabbaniS.A., GladuJ., MazarA.P., HenkinJ., GoltzmanD.Induction in human osteoblastic cells of the early response genes for jun and myc by the ATF of urokinase.J Cell Physiol1997; 172: 137–45.
61.
GoltzmanD.Mechanisms of the development of osteoblastic metastases.Cancer1997; 80: 1581–7.
62.
GuiseT.A., YinJ.J., MohammadK.S.Role of E-1 in osteoblastic bone metastases.Cancer2003; 97(Suppl): 779–84.
63.
HamdyF.C.Endothelin and skeletal metastases in hormone-refractory prostate cancer.Eur Urol2003; 2(Suppl): 15–9.
64.
NelsonJ.B., HedicanS.P., GeorgeD.J.Identification of ET-1 in the pathophysiology of metastatic cancer of the prostate.Nat Med1995; 1: 944–9.
65.
GranchiS., BrocchiS., BonaccorsiL.Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens.Prostate2001; 49: 267–77.
66.
LeeH.L., CooperC.R., PientaK.J.The effect of growth factors and cytokines on the growth of androgen sensitive and insensitive human prostate cancer cells in vitro.Proc Am Assoc Cancer Res2002; 43: A187.
67.
GuiseT.A.Molecular mechanisms of osteolytic bone metastases.Cancer2000; 88(Suppl 12); 2892–8.
68.
GuiseT.A.Parathyroid-hormone related protein and bone metastases.Cancer1997; 80(Suppl 8): 1572–80.
69.
MundyG.R.Mechanisms of bone metastasis.Cancer1997; 80(Suppl 8): 1546–56.
70.
IwamuraM., di Sant'AgneseP.A., WuG., BenninC.M., CockettA.T.K., DeftosL.J.Immunochemical localization of PTH-rP in human prostate cancer.Cancer Res1993; 53: 1724–6.
71.
CramerS.D., ChenZ., PeehlD.M.Prostate specific antigen cleaves PTH-rP in the PTH-like domain: inactivation of PTH-rP stimulated cAMP accumulation in mouse osteoblasts.J Urol1996; 156: 526–30.
72.
RankinW., GrillV., MartinT.J.Parathyroid hormone-related protein and hypercalcemia.Cancer1997; 80(Suppl 8): 1564–71.
73.
KeyLLJr., WolfW.C., GundbergC.M., RiesW.L.Superoxide and bone resorption.Bone1994; 15: 431–6.
74.
FongL., SmallE.J.Immunotherapy for prostate cancer.Semin Oncol2003; 30: 649–58.
75.
WolchokJ.D., GregorP.D., NordquistL.T., SlovinS.F., ScherH.I.DNA vaccines: an active immunization strategy for prostate cancer.Semin Oncol2003; 30: 659–66.
76.
AalamianM., TourkovaI., ChattaG.Inhibition of dendropoiesis by tumor-derived and purified PSA.J Urol2003; 170: 2026–30.
BladesR.A., KeatingP.J., McWilliamL.J., GeorgeN.J., StemP.L.Loss of HLA class I expression in prostate cancer. Implications for immunotherapy.Urology1995; 46: 681–7.
79.
TottermanTh, LoskogA., EssandM.The immunotherapy of prostate and bladder cancer.BJU Int2005; 96: 728–35.
80.
RodenA.C., MoserM.T., TriS.D.Augmentation of T-cell levels induced by androgen deprivation.J Immunology2004; 173: 6098–105.
81.
DrakeC.G., DoodyA.D., MihalyoM.A.Androgen ablation mitigates tolerance to a prostate cancer-restricted antigen.Cancer Cell2005; 7: 239–50.
82.
AkakuraK., SuzukiH., UedaT.Possible mechanism of dexamethasone therapy for prostate cancer.Prostate2003; 56: 106–9.
83.
PardalR., ClarkeM.F., MorrisonG.J.Applying the principles of stem-cell biology to cancer.Nat Rev Cancer2003; 3: 895–902.
ReyaT., CleversH.Wnt signalling in stem cells and cancer.Nature2005; 434: 842–50.
86.
HatfieldS.D., ShcherbataH.R., FisherK.A., NakaharaK., CarthewR.W., Ruotola-BakerH.Stem cell division is regulated by the microRNA pathway.Nature2005; 435: 974–8.
87.
MaitlandN.J., CollinsA.A tumor stem cell hypothesis for the origin of prostate cancer.BJU Int2005; 96: 1219–23.
88.
JalcutM.W., ReiterR.E.Role of PSCA in prostate cancer research.Curr Opin Urol2002; 12: 401–6.
89.
SinghA.S., FiggW.D.In vivo models of prostate cancer metastasis to bone.J Urol2005; 174: 820–6.
90.
HyytinenE.R., ThalmannG.N., ZhauH.E.Genetic changes associated with acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.Br J Cancer1997; 75: 190–5.
91.
RamaswamyS., RossK.N., LanderE.S., GolupT.R.A molecular signature of metastasis in primary solid tumours.Nat Genet2003; 33: 49–53.
92.
ChungL.W.The roles of myofibroblasts in prostate carcinogenesis.J Urol2004; 172: 2125–6.
93.
ChungL.W., HsiehC.L., LawA., SungS.Y., GardnerT.A., EgawaM.New targets for therapy in prostate cancer: modulation of stromal ephitelial interactions.Urology2003; 62: 447–54.
94.
GrunertS., JechlingerM., BeugH.Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.Nat Rev Mol Cell Biol2003; 4: 657–61.
95.
VashchenkoN., AbrahamssonP.A.Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.Eur Urol2005; 47: 147–55.
96.
XieS., LinH.K., NiJ.Regulation by androgen signaling in prostate cancer cells.Prostate2004; 60: 61–7.
